Analytical Lens: Exploring Denali Therapeutics Inc (DNLI)’s Financial Story Through Ratios

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Denali Therapeutics Inc (NASDAQ: DNLI) was $29.00 for the day, down -4.35% from the previous closing price of $30.32. In other words, the price has decreased by -$4.35 from its previous closing price. On the day, 1.85 million shares were traded. DNLI stock price reached its highest trading level at $30.54 during the session, while it also had its lowest trading level at $28.94.

Ratios:

Our analysis of DNLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.46 and its Current Ratio is at 12.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 13 ’24 when SATO VICKI L sold 1,020 shares for $30.00 per share. The transaction valued at 30,600 led to the insider holds 115,156 shares of the business.

VICKI LEE SATO bought 6,160 shares of DNLI for $172,234 on Sep 13 ’24. On Sep 03 ’24, another insider, SATO VICKI L, who serves as the Director of the company, sold 3,080 shares for $25.00 each. As a result, the insider received 77,007 and left with 116,176 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 4151784704 and an Enterprise Value of 3304500736. For the stock, the TTM Price-to-Sale (P/S) ratio is 3269.01 while its Price-to-Book (P/B) ratio in mrq is 2.99. Its current Enterprise Value per Revenue stands at 2608.13 whereas that against EBITDA is -6.681.

Stock Price History:

Over the past 52 weeks, DNLI has reached a high of $32.13, while it has fallen to a 52-week low of $14.56. The 50-Day Moving Average of the stock is 15.98%, while the 200-Day Moving Average is calculated to be 39.26%.

Shares Statistics:

DNLI traded an average of 1.05M shares per day over the past three months and 1379470 shares per day over the past ten days. A total of 138.39M shares are outstanding, with a floating share count of 119.08M. Insiders hold about 16.82% of the company’s shares, while institutions hold 84.18% stake in the company. Shares short for DNLI as of 1724976000 were 9014065 with a Short Ratio of 8.97, compared to 1722384000 on 7186932. Therefore, it implies a Short% of Shares Outstanding of 9014065 and a Short% of Float of 7.369999600000001.

Most Popular